Trials / Conditions / Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
4 registered clinical trials studyying Extrapulmonary Neuroendocrine Carcinoma (EP-NEC) — 4 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Not Yet Recruiting | A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, i NCT07488923 | Moonlight Bio, Inc | Phase 1 |
| Recruiting | Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expr NCT07278479 | Molecular Partners AG | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocri NCT07518602 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) NCT05652686 | Phanes Therapeutics | Phase 1 / Phase 2 |